On July 2, 2025, XtalPi (2228.HK) announced the completion of its Pre-Seed investment in Foundry BioSciences, a technology platform leveraging generative AI for protein design to advance anti-aging products and drug development. The funding round, totaling several million USD, was led by XtalPi with participation from Taihill Venture, Yayi Capital, and other professional investment firms. The funds will primarily support continuous upgrades to the technology platform, expansion of the core team, and the advancement of multiple research projects aimed at industrial transformation, driving the cutting-edge application of AI-driven protein language models in longevity science.
Foundry BioSciences is a biotechnology company at the forefront of AI-driven protein design and longevity science. Founded by interdisciplinary scientists and technology experts from MIT, Princeton University, and Harvard University, the company is committed to developing next-generation protein language models through deep learning technology. These models enable protein function prediction, sequence optimization, and end-to-end biomolecular design. The team’s research has been widely applied to critical areas tied to human health and lifespan, including immune regulation, metabolic health, neuroprotection, and tissue repair and regeneration. Leveraging world-leading protein evolution algorithms, Foundry BioSciences is building a digital foundation that spans sequence discovery to efficacy validation, enabling rapid design and efficient iteration of anti-aging target proteins. This work supports the development of high-quality, effective anti-aging drugs, supplements, and cosmetic ingredients.
Foundry BioSciences’ co-founder and Chief Scientific Officer, Kaiyi Jiang, earned his Ph.D. in Biological Engineering from MIT at age 26. Mentored by CRISPR gene-editing pioneers Omar Abudayyeh and Jonathan Gootenberg (from Feng Zhang’s lab) and immunology and bioengineering expert Michael Birnbaum, Dr. Jiang focused his doctoral research on RNA-guided systems, protein engineering, and synthetic biology technologies. His first-author breakthroughs include the first eukaryotic RNA-guided DNA nuclease, a highly sensitive mammalian cell state sensor, and a best-in-class AI-guided few-shot protein engineering model. Published in top journals such as Nature, Science, Nature Biotechnology, and Nature Materials, his work has resulted in six international patents and the founding of three startups. Dr. Jiang currently serves as a faculty member in Princeton University’s Department of Biological Engineering, where he holds the distinction of being the youngest professor hired without postdoctoral training in the department’s history. He is also the inaugural Amgen Science Fellow, collaborating with Professor Howard Chang to design novel therapeutic approaches using deep learning and synthetic biology. His achievements have earned him accolades such as MIT Technology Review’s Innovators Under 35 Asia Pacific and the MIT Wishnok Prize.
Following this funding round, Foundry BioSciences will partner closely with XtalPi. By combining its advanced expertise in biology and protein design with XtalPi’s high-throughput synthesis and automated experimental capabilities, the two companies will co-develop a comprehensive pipeline platform for anti-aging therapies and products. This platform will span functional ingredient design and screening, customized formulation development, and the creation of oral and topical anti-aging consumer products, as well as Phase I/II clinical innovative therapies. By seamlessly integrating “algorithm-driven” research with “automated experimental validation,” this efficient R&D model will significantly reduce the time and cost from concept to product or therapy, delivering consumer-grade solutions and groundbreaking biopharmaceuticals to the global anti-aging market and benefiting a broader population.
Dr. Shuhao Wen, Chairman of XtalPi, commented: “Longevity science represents the ultimate pursuit of human health. The Foundry BioSciences team brings deep scientific insight and exceptional execution capabilities, redefining protein design with generative AI and injecting transformative innovation into this untapped market. As both an investor and strategic partner, XtalPi will work hand-in-hand with them to build a research foundation that merges cutting-edge algorithms with automated experimental workflows, accelerating the transformation of challenging longevity targets into world-changing outcomes.”
Jingjing Chai, co-founder and CEO of Foundry BioSciences, a Harvard University graduate with extensive experience in AI+ biotech investment and incubation, added: “We founded Foundry BioSciences to bring scientific breakthroughs that enhance human health and lifespan from the lab to the marketplace using state-of-the-art AI protein language models. We’re honored to have the support of XtalPi and multiple leading investment firms, which not only validates our technological vision but also provides a strong foundation for platform iteration, team growth, and accelerated commercialization. We look forward to collaborating with more partners to unlock the full potential of AI-powered longevity technology.”
About Foundry BioSciences
Founded by pioneering scientists from MIT, Princeton, and Harvard, Foundry BioSciences is a technology platform that harnesses generative AI for protein design to advance anti-aging products and drug development. The company specializes in creating novel, highly bioactive protein sequences using advanced AI techniques, targeting key areas of aging mitigation such as immune regulation, metabolic health, neuroprotection, and tissue regeneration. Its core offerings include AI protein computation, consumer-grade health products, anti-aging drugs, and an open collaboration platform.
Website: www.foundrybio.ai ｜Email: info@foundrybio.ai
